Metabolic profile directed aptamer medicinal chemistry

• US 20090075342A1
• Filed: 04/30/2008
• Published: 03/19/2009
• Est. Priority Date: 04/26/2005
• Status: Abandoned Application

• Current Assignee: Archemix Corp. (Baxter International Inc.)
• Original Assignee: Archemix Corp. (Baxter International Inc.)
• Inventors: Donahue, Christine P., Wilson, Charles, Hutabarat, Renta, Cload, Sharon, Thompson, Kristin
• Application Number:
  US12/150,855
• Publication Number:
  US 20090075342A1
• Time in Patent Office: Days
• US Class Current: 435/89
• CPC Class Codes: C12N 15/111 General methods applicable to biologically active non-coding nucleic acids
• CPC Class Codes: C12N 15/115 Aptamers, i.e. nucleic acids binding a target molecule specifically and with high affinity without hybridising therewith ; Nucleic acids binding to non-nucleic acids, e.g. aptamers
• CPC Class Codes: C12N 2310/16 Aptamers
• CPC Class Codes: C12N 2310/315 Phosphorothioates
• CPC Class Codes: C12N 2310/317 with an inverted bond, e.g. a cap structure
• CPC Class Codes: C12N 2310/321 2'-O-R Modification
• CPC Class Codes: C12N 2310/331 Universal or degenerate base
• CPC Class Codes: C12N 2310/351 Conjugate
• CPC Class Codes: C12N 2310/3521 Methyl
• CPC Class Codes: C12N 2320/13 in a process of directed evolution, e.g. SELEX, acquiring a new function
• CPC Class Codes: C12N 2330/30 chemically synthesised

Abstract

The present invention provides materials and methods for enhancing aptamers. More specifically, the materials and methods of the present invention are directed toward the modification of aptamers by the identification of one or more cleavage sites, and introduction of a chemical substitution at a position proximal to the cleavage site(s). Such aptamers are useful for the treatment of disease, in diagnostic and detection applications, and/or research, e.g., target validation.

Claims

1. ) A method for modifying an aptamer comprising the steps of:

a) incubating a parent aptamer with a test fluid to result in a mixture;

b) analyzing the mixture to identify metabolites of the parent aptamer, thereby detecting at least one aptamer cleavage site in the parent aptamer; and

c) introducing a chemical substitution at a position proximal to the at least one aptamer cleavage site to result in a modified aptamer.

2. ) The method of claim 1, wherein the test fluid is a biological matrix, a low pH fluid, a high pH fluid, a room temperature fluid or a body temperature fluid.

3. ) The method of claim 2, wherein the biological matrix is selected from the group consisting of one or more of:

serum;

plasma;

cerebral spinal fluid;

tissue extracts, including cytosolic fraction, S9 fraction and microsomal fraction;

aqueous humour;

vitreous humour and tissue homogenates.

4. ) The method of claim 2, wherein the biological matrix is derived from a species selected from the group consisting of one or more of:

mouse, rat, monkey, pig, human, dog, guinea pig and rabbit.

5. ) The method of claim 1, wherein the test fluid comprises at least one purified enzyme.

6. ) The method of claim 5, wherein the enzyme is selected from the group consisting of snake venom phosphodiesterase and DNAse 1.

7. ) The method of claim 1, wherein the analyzing step comprises analyzing the mixture using liquid chromatography and mass spectrometry.

8. ) The method of claim 1, wherein the analyzing step comprises analyzing the mixture using electron spray ionization liquid chromatography mass spectrometry, polyacrylamide gel electrophoresis or capillary electrophoresis to determine a position of the at least one aptamer cleavage site.

9. ) The method of claim 1, wherein the analyzing step comprises analyzing the mixture using a bioanalytical method selected from the group consisting of one or more of:

denaturing polyacrylamide gel electrophoresis, capillary electrophoresis, HPLC, LC/MS, LC/MS/MS, LC/MS/MS/MS, ESI-LC/MS, ESI-LC/MS/MS and ESI-LC/MS/MS/MS.

10. ) The method of claim 1, wherein the chemical substitution is selected from the group consisting of:

a chemical substitution at a sugar position;

a chemical substitution at a base position and a chemical substitution at an internucleotide linkage.

11. ) The method of claim 10, wherein the chemical substitution is selected from the group consisting of:

a purine substitution for a pyrimidine;

a 2′

-deoxy dihydrouridine substitution for a uridine;

a 2′

-deoxy-5-methyl cytidine for a cytidine;

a 2-amino purine substitution for a purine;

a phosphorothioate substituted for a phosphodiester;

a phosphorodithioate substituted for a phosphodiester;

a deoxynucleotide substituted for a 2′

-OH nucleotide;

a 2′

-OMe nucleotide, a 2′

-fluoro nucleotide or a 2′

-O-methoxyethyl nucleotide substituted for a 2′

-OH or deoxynucleotide;

the addition of a 3′

cap or a 5′

cap; and

the addition of a PEG or PAG polymer.

12. ) The method of claim 11, wherein the chemical substitution is a phosphorothioate or phosphorodithioate substituted for a phosphodiester.

13. ) The method of claim 12, wherein the chemical substitution is a phosphorothioate substituted for a phosphodiester.

14. ) The method of claim 11, wherein the chemical substitution is a 2′

-OMe nucleotide, a 2′

-fluoro nucleotide or a 2′

-methoxyethyl nucleotide substituted for a 2′

-OH or deoxynucleotide.

15. ) The method of claim 14, wherein the chemical substitution is a 2′

-OMe nucleotide substituted for a 2′

-OH or deoxynucleotide.

16. ) The method of claim 1, wherein the modified aptamer binds a target with the same or better affinity than the parent aptamer.

17. ) The method of claim 1, wherein the proximal position comprises a position selected from the group consisting of:

a position immediately 5′

to the aptamer cleavage site, a 5′

position at or within three nucleotides of the aptamer cleavage site, a position immediately 3′

to the aptamer cleavage site, a 3′

position at or within three nucleotides of the aptamer cleavage site, and a position at the cleaved internucleotide linkage.

18. ) The method of claim 17, wherein the proximal position is at the cleaved internucleotide linkage and the chemical substitution is at a phosphate position.

19. ) The method of claim 17, wherein the proximal position is 5′

or 3′

to the aptamer cleavage site and the chemical substitution is at a sugar or base position.

20. ) The method of claim 1, wherein the introducing step further comprises introducing more than one chemical substitution at one or more cleavage sites or into a cleavage site or both.

21. ) The method of claim 1, wherein the method further comprises the step of testing the stability of the modified aptamer in the test fluid.

22. ) The method of claim 21, comprising repeating the incubating, analyzing, introducing and testing steps iteratively.

23. ) The method of claim 21, wherein the modified aptamer is more stable in the test fluid than the parent aptamer.

24. ) The method of claim 21, wherein the stability is assessed by the percent of modified aptamer that remains intact in the test fluid as compared to the percent of the parent aptamer that remains intact in the test fluid.

25. ) The method of claim 24, wherein the percent of intact aptamer is assessed by a bioanalytical method selected from the group consisting of one or more of:

denaturing polyacrylamide gel electrophoresis, capillary electrophoresis, HPLC, LC/MS, LC/MS/MS, LC/MS/MS/MS, ESI-LC/MS, ESI-LC/MS/MS and ESI-LC/MS/MS/MS.

26. ) The method of claim 23, wherein the modified aptamer is at least 2 fold more stable in the test fluid than the parent aptamer.

27. ) The method of claim 23, wherein the modified aptamer is at least 5 fold more stable in the test fluid than the parent aptamer.

28. ) The method of claim 23, wherein the modified aptamer is at least 10′

fold more stable in the test fluid than the parent aptamer.

29. ) The method of claim 1, wherein the method further comprises the step of determining a dissociation constant of the modified aptamer for a target.

30. ) The method of claim 29, wherein the method comprises selecting a modified aptamer having a dissociation constant for its target that is the same or less than a dissociation constant of the parent aptamer.

31. ) The method of claim 1, wherein the modified aptamer binds a target having a biological activity, and wherein the method further comprises the step of measuring the biological activity of the target in the presence and absence of the aptamer.

32. ) The method of claim 31, wherein the biological activity is measured by an ELISA assay or a cell-based assay.

33. ) The method of claim 1, wherein the biological activity of the target upon binding the modified aptamer is the same or better than that of the biological activity of the target upon binding the parent aptamer.

34. ) A method for modifying an aptamer comprising the steps of:

a) incubating a parent aptamer with a biological matrix that contains an enzyme to result in a mixture;

b) analyzing the mixture to identify metabolites of the parent aptamer, thereby detecting at least one aptamer cleavage site in the parent aptamer; and

c) introducing a chemical substitution at a position proximal to the at least one aptamer cleavage site to result in a modified aptamer.

35. ) A method for enhancing the stability of an aptamer comprising the steps of:

a) incubating a parent aptamer with a test fluid to result in a mixture;

b) analyzing the mixture to identify metabolites of the parent aptamer, thereby detecting at least one aptamer cleavage site in the parent aptamer; and

c) introducing a chemical substitution at a position proximal to the at least one aptamer cleavage site to result in a modified aptamer.

36. ) A method for enhancing the stability of an aptamer to exonucleases and endonucleases comprising the steps of:

a) incubating a parent aptamer with a test fluid to result in a mixture;

b) analyzing the mixture to identify metabolites of the parent aptamer, thereby detecting at least one aptamer cleavage site in the parent aptamer; and

c) introducing a chemical substitution at a position proximal to the at least one aptamer cleavage site to result in a modified aptamer.